Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
Rezolute stock sinks 87% as hypoglycemia drug fails ph. 3 test
Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application.
James Waldron
Dec 11, 2025 9:45am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
Dyne readies FDA push after DMD exon 51 med excels in trial
Dec 8, 2025 10:50am
ASH: Anito-cel strengthens potential as Kite preps for launch
Dec 7, 2025 11:52am
ASH: Star antibody sparkles in preview of possible ph. 3 success
Dec 7, 2025 9:40am
Fierce Pharma
With site 'irregularities,' BMS delays key Cobenfy readout
Dec 3, 2025 10:14am
